These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38054562)
1. Concordance of Immunohistochemistry and Fluorescence In Situ Hybridization in the Detection of Anaplastic Lymphoma Kinase (ALK) and Ros Proto-oncogene 1 (ROS1) Gene Rearrangements in Non-Small Cell Lung Carcinoma: A 4.5-Year Experience Highlighting Challenges and Pitfalls. Nambirajan A; Sood R; Khatoon W; Malik PS; Mohan A; Jain D Arch Pathol Lab Med; 2024 Aug; 148(8):928-937. PubMed ID: 38054562 [TBL] [Abstract][Full Text] [Related]
2. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization. Luk PP; Selinger CI; Mahar A; Cooper WA Arch Pathol Lab Med; 2018 Aug; 142(8):922-928. PubMed ID: 29902067 [TBL] [Abstract][Full Text] [Related]
3. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695 [TBL] [Abstract][Full Text] [Related]
4. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples. Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer. Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706 [TBL] [Abstract][Full Text] [Related]
6. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma. Piton N; Ruminy P; Gravet C; Marchand V; Colasse É; Lamy A; Naoures Mear CL; Bibeau F; Marguet F; Guisier F; Salaün M; Thiberville L; Jardin F; Sabourin JC Lab Invest; 2018 Mar; 98(3):371-379. PubMed ID: 29251734 [TBL] [Abstract][Full Text] [Related]
7. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833 [TBL] [Abstract][Full Text] [Related]
8. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111 [TBL] [Abstract][Full Text] [Related]
9. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience. Singh A; Kumar R; Shetty O; Desai S; Rane S Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590 [TBL] [Abstract][Full Text] [Related]
10. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756 [TBL] [Abstract][Full Text] [Related]
11. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. Sholl LM; Weremowicz S; Gray SW; Wong KK; Chirieac LR; Lindeman NI; Hornick JL J Thorac Oncol; 2013 Mar; 8(3):322-8. PubMed ID: 23407557 [TBL] [Abstract][Full Text] [Related]
12. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients. Bozzetti C; Nizzoli R; Tiseo M; Squadrilli A; Lagrasta C; Buti S; Gasparro D; Zanoni D; Majori M; De Filippo M; Mazzoni F; Maddau C; Naldi N; Sammarelli G; Frati C; Pinto C; Ardizzoni A Diagn Cytopathol; 2015 Nov; 43(11):941-6. PubMed ID: 26152804 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls. Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018 [TBL] [Abstract][Full Text] [Related]
14. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512 [TBL] [Abstract][Full Text] [Related]
15. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns. Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M Clin Lung Cancer; 2019 Jul; 20(4):e421-e429. PubMed ID: 30898567 [TBL] [Abstract][Full Text] [Related]
16. ALK and ROS1 testing on lung cancer cytologic samples: Perspectives. Pisapia P; Lozano MD; Vigliar E; Bellevicine C; Pepe F; Malapelle U; Troncone G Cancer Cytopathol; 2017 Nov; 125(11):817-830. PubMed ID: 28743163 [TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age. Ke L; Xu M; Jiang X; Sun X Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372 [TBL] [Abstract][Full Text] [Related]
18. Multiplex fluorescence in situ hybridization testing for anaplastic lymphoma kinase and c-ros oncogene 1 gene rearrangements on cytology smears in lung adenocarcinomas: comparative study with formalin-fixed paraffin-embedded sections. Nambirajan A; Rana D; Samant K; Prabakaran A; Malik P; Jain D J Am Soc Cytopathol; 2022; 11(3):154-164. PubMed ID: 35148960 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459 [TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1. Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]